# Trending Content OS — Daily Run
**Run date:** 2026-10-24 | **Niche:** Health & Wellness | **Site URL:** not configured (competitor-fallback used)

---

## 1. Preflight Summary

| Check | Status |
|---|---|
| All 7 configs + CLAUDE.md loaded | ✅ |
| `site_niche` / `target_audience` set | ✅ |
| `site_url` set | ⚠️ Empty — self-check skipped, competitor-list fallback used for duplicate/SERP context |
| SerpAPI connected | ✅ |
| Google Trends available | ✅ (`serpapi_prefetch` block injected — treated as primary search_velocity input) |
| Google News Radar injected | ✅ (144 unique headlines, 12 queries) |
| Deferred topics (`data/deferred_topics.yaml`) | None past `recheck_on` date |
| Run history recurrence check | Toothpaste recall, GLP-1 recall, AI-diagnostic study, pertussis GBD, Marshall Faulk Parkinson's all appeared yesterday (2026-10-23) → treated as `existing`, excluded unless new development |

**Next action:** `run_signal_listener` → proceed.

---

## 2. Google News Radar Coverage Summary

| Cluster | Disposition | Reason |
|---|---|---|
| **FDA recalls** — toothpaste, GLP-1 | Existing (skip) | Covered yesterday, no new development |
| **FDA recall — Class I E. coli cheese recall (13 states)** [[Newsweek]](https://www.newsweek.com/cheese-recall-states-highest-warning-issued-e-coli-12592463) | **Monitor (P5)** | Only 1 source in evidence; breaking-recall exception requires 3+ corroborating sources or a direct FDA/USDA notice — neither met |
| **Salmonella/oysters outbreak (VA)** [[VDH]](https://www.vdh.virginia.gov/news/salmonella-outbreak-oysters/) | **Rejected** | Stale — 4 days old, exceeds 72h P2 recall freshness ceiling; single state-only source |
| **Oncology clinical trials** — NIH T-cell therapy, Mayo KRAS vaccine, PTSD remission, pulmonary denervation | Split: 2 retained, rest monitored | See priority board + monitor list below |
| **AI-outperforms-physicians (Microsoft)** | Existing (skip) | Covered yesterday |
| **"Practice-changing" lung cancer immunotherapy** [[NBC News]](https://www.nbcnews.com) (drove the live "cancer" Trends spike) | **Rejected** | Unverifiable health claim — headline-only evidence, no journal/trial ID/researcher identified in available sourcing |
| **Women's health executive order / new NIH Division** [[HHS.gov]](https://www.hhs.gov/press-room/trump-flotus-womens-health-executive-order-new-nih-division.html) | **Retained** | Strong Trends convergence (multiple related rising queries) + tier-1 institutional source |
| **Health insurance costs** (KFF/Commonwealth/NYT/NPR/Time) | **Rejected** | Off-category — insurance economics/policy, thin behavioral-health angle, weak audience fit |
| **Hospital M&A** (Hackensack-Hunterdon, CentraCare-Stellis) | **Rejected** | Excluded category — local hospital business news |
| **Pharma/AI industry** (Oracle-AstraZeneca, FDA AI trial-algorithm guidance) | **Rejected** | Excluded category — pure pharma/industry business |
| **CDC Public Health Data Strategy** | **Rejected** | Off-category — internal/bureaucratic, low audience relevance |
| **Nature "personal health agent" AI paper** | **Rejected** | Off-category — AI-research audience, not consumer health |
| **WHO physician workforce gap / Ebola vaccine trial (DRC)** | **Rejected / Monitor** | Workforce gap off-category; Ebola trial monitored (trend_strength 49, just under threshold) |
| **Campus/local wellness fairs** (Purdue, UTSA, Georgia Tech, Carroll, Case Western, Marquette, Fort McCoy) | **Rejected** | Off-category — local/institutional, no national audience relevance |
| **Therme DC wellness resort** | **Rejected** | Off-category — local real-estate/community dispute |
| **Trisha Yearwood weight loss** | **Rejected** | Excluded category — celebrity wellness, no evidence angle |
| **"Wellness darties" (CNN)** | **Rejected** | Weak signal — cultural curiosity, no health-evidence angle |
| **Wellness influencer misinformation event (Guardian)** | **Monitor** | Good skepticism angle but insufficient trend corroboration this cycle |
| **Supplement strips (WSJ)** | **Monitor** | Cultural/product trend, no velocity signal |
| **ADHD medication self-harm study** | **Monitor** | Trend_strength below threshold (34) |
| **Tea & heart-health study** (Trends rising query only, no matching article) | **Monitor** | Real search demand, no corroborating article found — flag for manual research |
| **GLP-1/Cagrisema weight-loss stats** | **Monitor** | Search-only signal, no news corroboration |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: 2026-10-24T00:00:00Z
  run_completed_at: 2026-10-24T00:00:00Z
  total_signals_reviewed: 151   # 144 Google News Radar + 7 Google Trends topic clusters
  total_signals_retained: 3
  total_rejected: 16
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 7
    brand_safety: 1
    duplicate: 5
    weak_signal: 1
    unverified_claim: 1
    other: 1
  highest_priority_topic: "NIH precision T-cell therapy stalls treatment-resistant cancers"
  strongest_signal_source: "NIH.gov (tier-1 institutional, direct trial sponsor)"
  tools_unavailable: []
  notes: >
    Google News Radar accounted for in full (see cluster table above). Several editorially
    attractive stories (PTSD remission trial, ADHD/self-harm study, Mayo pancreatic vaccine
    just under threshold at 51, WHO Ebola trial at 49) failed the trend_strength ≥50 floor
    due to single-source evidence and flat/absent Google Trends corroboration — routed to
    Monitor rather than forced through. The NBC lung-cancer immunotherapy story is the one
    real missed opportunity: it is driving the live "cancer" Trending Now spike but could not
    be scored without a traceable primary source (journal/trial ID). Recommend manual
    follow-up to locate the underlying study before next run. site_url not configured —
    self-check skipped; competitor-list used for SERP-gap context only.
```

---

## 4. Skill 02b Routing Summary

| Candidate | Risk Type | Primary Source | Gate Result |
|---|---|---|---|
| NIH T-cell therapy | clinical_trial | NIH.gov press release (direct sponsor) | **Pass** |
| Women's health executive order | n/a — policy_or_regulatory_change | HHS.gov | **Not applicable** (not a drug/treatment/supplement/recall/dosage claim) |
| Mayo KRAS pancreatic vaccine | clinical_trial | Mayo Clinic News Network (institutional) | **Pass** — flagged: immune-response finding ≠ efficacy/survival outcome |
| Cheese recall (E. coli, 13 states) | recall | None directly retrieved; 1 source only | **Monitor** — breaking-recall exception not met, held for P5 |
| Lung cancer immunotherapy (NBC) | drug_or_treatment_claim / study | None — headline only | **Reject** — unverifiable health claim |
| Salmonella/oysters outbreak | recall | VDH.gov (single state source) | **Not scored — rejected on freshness before gate relevance** |

---

## 5. Final Priority Board

```yaml
priority_board:
  - priority_level: P1
    publish_timing: immediate
    topic: "NIH precision T-cell therapy stalls treatment-resistant cancers in clinical trial"
    primary_entity: "NIH (National Institutes of Health)"
    signal_type: clinical_trial
    allowed_category: "medical research and clinical trials"
    trend_strength_score: 56
    opportunity_score: 79
    discover_score: 4
    urgency: today
    confidence: medium
    content_status: new
    source_count: 1
    recommended_angle: "Explain what this precision T-cell approach actually does differently, and what 'stalls' means for patients who've exhausted other options"
    why_now: "Fresh NIH institutional release (Oct 23); general cancer search interest is elevated right now (Google Trends 'cancer' breakout)"
    primary_headline: "NIH-Backed T-Cell Therapy Shows Promise Against Treatment-Resistant Cancers in Early Trial"
    next_steps: "Assign writer; verify independent press pickup (STAT/Reuters) and confirm trial phase/patient count from NIH release before publishing"
    notes: "Single-source but tier-1 institutional/primary (trial sponsor itself) — confidence held at medium pending broader pickup"

  - priority_level: P2
    publish_timing: short_term
    topic: "HHS executive order creates new NIH Division for Women's Health Research"
    primary_entity: "HHS / NIH Division for Women's Health"
    signal_type: policy_or_regulatory_change
    allowed_category: "women's health"
    trend_strength_score: 77
    opportunity_score: 76
    discover_score: 3
    urgency: this_week
    confidence: medium
    content_status: new
    source_count: 1
    recommended_angle: "What the new NIH division actually changes for women's health research funding and priorities — not the politics of the signing"
    why_now: "Multiple Google Trends rising queries ('women's health executive order,' 'womens health task force') confirm active search demand 5 days post-signing"
    primary_headline: "Trump Administration Launches New NIH Division Dedicated to Women's Health Research"
    next_steps: "Assign writer; confirm scope of new division's mandate via HHS.gov; strictly avoid partisan framing per brand_safety_rules (allow_politics: false)"
    notes: "⚠️ Borderline category pass — retained under borderline_criteria (audience_relevance ≥70, clear research angle, not excluded). Frame around research impact only."

  - priority_level: P3
    publish_timing: scheduled
    topic: "Mayo Clinic investigational vaccine generates immune response to KRAS mutations in pancreatic cancer"
    primary_entity: "Mayo Clinic"
    signal_type: clinical_trial
    allowed_category: "medical research and clinical trials"
    trend_strength_score: 51
    opportunity_score: 73
    discover_score: 3
    urgency: this_week
    confidence: medium
    content_status: new
    source_count: 1
    recommended_angle: "Explain what 'immune response' means at this early trial stage vs. an actual treatment — fills a real explainer gap"
    why_now: "Fresh Mayo Clinic institutional release (Oct 23); pancreatic cancer coverage is thin relative to other oncology trial news this week"
    primary_headline: "Mayo Clinic's Investigational Vaccine Triggers Immune Response to Pancreatic Cancer Mutations"
    next_steps: "Queue for this week; confirm trial phase and immune-response specifics from Mayo release"
    notes: "Borderline trend score (51/50 floor) — justified by tier-1 institutional sourcing; confirm before escalating priority"

summary:
  total_topics: 3
  high_priority_count: 1
  immediate_actions: "Assign NIH T-cell therapy brief today; verify secondary pickup before publish"
```

---

## 6. Editorial Briefs

### P1 — NIH Precision T-Cell Therapy

```yaml
brief:
  primary_headline: "NIH-Backed T-Cell Therapy Shows Promise Against Treatment-Resistant Cancers in Early Trial"
  alternate_headlines:
    - "A New Precision T-Cell Therapy Just Stalled Some of the Hardest-to-Treat Cancers"
    - "What NIH's Latest T-Cell Trial Means for Patients Who've Run Out of Options"
  topic: "NIH precision T-cell therapy, treatment-resistant cancers"
  primary_entity: "National Institutes of Health (NIH)"
  search_intent: "Informational / evaluative — 'is this a real breakthrough, who does it help'"
  angle: "Explain the mechanism in plain language and set realistic expectations about trial stage, rather than repeating the press-release framing"
  why_now: "Direct NIH institutional release (Oct 23); general cancer-search interest is elevated in real time per Google Trends"
  integrity_flags:
    - "⚠️ Integrity note: Trial result is early-stage ('stalls' progression) — avoid implying cure; clarify trial phase and patient population size."
    - "⚠️ Integrity note: Single-source coverage (NIH release only) — verify with independent oncology reporting before publishing."
  outline:
    intro: "Lead with what changed for patients who've exhausted standard treatment options"
    sections: ["How the T-cell therapy differs from existing approaches", "What 'stalling' progression actually means clinically", "Trial size, phase, and population", "What comes next before this reaches patients broadly"]
    conclusion: "Managed expectations: promising signal, not an approved treatment"
  key_data_points: ["Trial outcome as described in NIH release — confirm specific response/stall rate before publishing"]
  source_plan:
    - { publisher: "NIH", url: "https://www.nih.gov/news-events/news-releases/precision-t-cell-therapy-stalls-treatment-resistant-cancers-clinical-trial", tier: 1, used_for: "Primary trial announcement and data" }
  evidence_requirements: "Heavy — named researcher, trial phase, sample size required before draft"
  expert_sources:
    - { type: "Oncologist / immunologist", name: "Named NIH principal investigator from the release", reason: "Primary-source credibility" }
  internal_links: []
  visual_brief: "Simple explainer graphic of T-cell mechanism; avoid stock images implying 'cure'"
  seo:
    primary_keyword: "NIH T-cell therapy cancer trial"
    supporting_keywords: ["treatment-resistant cancer", "precision T-cell therapy", "NIH clinical trial cancer"]
    format: "News explainer, 900–1100 words"
    schema_markup: "NewsArticle"
    cluster: "medical research and clinical trials"
  discover_notes: "Discover score 4 — named entity + durable Q&A fit + primary source; SERP gap exists for plain-language explainer"
  key_takeaways: ["Early-stage but real signal for hard-to-treat cancers", "Not yet an approved treatment", "Monitor for independent confirmation"]
  estimated_word_count: "900-1100"
execution_notes: "Hold publish until independent pickup (STAT/Reuters) confirms trial details."
confidence: medium
```

### P2 — Women's Health Executive Order / New NIH Division

```yaml
brief:
  primary_headline: "Trump Administration Launches New NIH Division Dedicated to Women's Health Research"
  alternate_headlines:
    - "What the New Women's Health Executive Order Actually Changes for Research Funding"
    - "A New Federal Task Force Is Reshaping How Women's Health Gets Studied"
  topic: "HHS executive order, new NIH Division for Women's Health"
  primary_entity: "HHS / NIH Division for Women's Health"
  search_intent: "Informational — 'what is the new women's health executive order / task force'"
  angle: "Strip out the politics; explain concretely what the new division does, what it funds, and what changes for women's health research"
  why_now: "Google Trends shows multiple live rising queries tied to this exact event 5 days post-signing — active, unmet search demand"
  integrity_flags:
    - "⚠️ Integrity note: Originates from a politically-charged executive action — frame around research/funding impact only, per brand_safety_rules (allow_politics: false)."
  outline:
    intro: "What the order creates (new NIH division/task force) and why it matters to patients/researchers"
    sections: ["What the new division is mandated to do", "How this differs from existing NIH structure", "What conditions/research areas stand to benefit", "Open questions — funding, timeline, leadership"]
    conclusion: "What to watch for next (appointments, funding allocations)"
  key_data_points: ["Scope and mandate as stated in HHS release — confirm exact structure before publishing"]
  source_plan:
    - { publisher: "HHS.gov", url: "https://www.hhs.gov/press-room/trump-flotus-womens-health-executive-order-new-nih-division.html", tier: 1, used_for: "Primary policy announcement" }
  evidence_requirements: "Moderate — primary government source sufficient, avoid partisan commentary"
  expert_sources:
    - { type: "Health policy researcher", name: "University- or NIH-affiliated commentator on women's health research funding", reason: "Independent context on research impact" }
  internal_links: []
  visual_brief: "Neutral institutional imagery (NIH building, research lab) — avoid political imagery"
  seo:
    primary_keyword: "women's health executive order NIH division"
    supporting_keywords: ["women's health task force", "NIH women's health research funding"]
    format: "News explainer, 800-1000 words"
    schema_markup: "NewsArticle"
    cluster: "women's health"
  discover_notes: "Discover score 3 — strong entity/question fit, but SERP likely saturated with political framing; differentiate via policy-impact angle"
  key_takeaways: ["New NIH division focused on women's health research", "Policy action, not yet showing funding specifics", "Angle: research impact, not politics"]
  estimated_word_count: "800-1000"
execution_notes: "Confirm full division mandate directly from HHS.gov before drafting; strictly non-partisan framing."
confidence: medium
```

### P3 — Mayo Clinic Pancreatic Cancer Vaccine (concise brief)

```yaml
brief:
  headline: "Mayo Clinic's Investigational Vaccine Triggers Immune Response to Pancreatic Cancer Mutations"
  topic: "Mayo Clinic KRAS pancreatic cancer vaccine, early trial"
  angle: "Explain clearly that 'immune response' is an early biological signal, not proof the vaccine prevents or treats cancer — fills an explainer gap competitors are likely to skip"
  key_data_points: ["Immune response generated against KRAS mutations — confirm trial phase/sample size from Mayo release"]
  integrity_flags:
    - "⚠️ Integrity note: Immune-response finding ≠ clinical efficacy or survival benefit — must be stated explicitly, early-phase trial."
  expert_type_needed: "Oncologist or named Mayo researcher from the release"
  seo:
    primary_keyword: "Mayo Clinic pancreatic cancer vaccine KRAS"
    format: "News explainer, 500-700 words"
    serp_difficulty: Medium
  sources:
    - { publisher: "Mayo Clinic News Network", url: "https://newsnetwork.mayoclinic.org/discussion/investigational-vaccine-generates-immune-response-to-kras-mutations-in-pancreatic-cancer-study/" }
  estimated_word_count: "500-700"
```

---

## 7. Rejected Topics Log

| Topic | Reason |
|---|---|
| Brush Buddies toothpaste recall | Duplicate — covered 2026-10-23, no new development |
| GLP-1 tirzepatide sterility recall | Duplicate — covered 2026-10-23, no new development |
| AI outperforms physicians (Microsoft study) | Duplicate — covered 2026-10-23, no new development |
| Pertussis GBD study 1990–2023 | Duplicate — covered 2026-10-23, no new development |
| Marshall Faulk Parkinson's diagnosis | Duplicate — covered 2026-10-23, no new development |
| "Practice-changing" lung cancer immunotherapy (NBC) | Unverifiable health claim — no traceable journal/trial ID in available evidence |
| Salmonella/oysters outbreak (Virginia) | Stale — exceeds 72h recall freshness ceiling; single state source only |
| Employer health insurance costs cluster (KFF/Commonwealth/NYT/NPR/Time) | Off-category — insurance economics, weak audience-behavior angle |
| Hospital mergers (Hackensack-Hunterdon, CentraCare-Stellis) | Excluded category — local hospital business news |
| Oracle-AstraZeneca AI trials partnership; FDA AI trial-algorithm guidance | Excluded category — pure pharma/industry business |
| CDC Public Health Data Strategy milestones | Off-category — internal/bureaucratic, low audience relevance |
| Nature "personal health agent" AI paper | Off-category — AI-research audience, not consumer health |
| WHO physician workforce gap | Off-category — low direct consumer relevance |
| Campus/local wellness fairs (7 schools/bases) | Off-category — local/institutional, not national audience |
| Therme DC wellness resort debate | Off-category — local real-estate dispute |
| Trisha Yearwood weight loss | Brand safety — excluded celebrity wellness category, no evidence base |
| "Wellness darties" (CNN) | Weak signal — cultural curiosity, no health-evidence angle |

---

## 8. Integrity Flags (Consolidated)

- ⚠️ **NIH T-cell therapy** — early-stage result; avoid implying cure; single-source pending independent confirmation.
- ⚠️ **Women's health executive order** — politically-charged origin; frame strictly around research/funding impact, not partisan politics.
- ⚠️ **Mayo pancreatic vaccine** — immune response ≠ clinical efficacy; must state early-phase status explicitly.

---

## 9. Run Notes

- Three candidates cleared both scoring thresholds; several editorially appealing stories (PTSD remission trial, ADHD/self-harm study, WHO Ebola trial, Mayo trial on first pass) sat at or just below `minimum_trend_strength_score` (50) due to single-source evidence and flat/absent Trends corroboration — held in Monitor rather than forced through, consistent with "default answer is no."
- The NBC lung-cancer immunotherapy story is the day's biggest missed opportunity: it's driving a live Google Trends breakout but lacks a traceable primary source in available data. Recommend manual research follow-up before next run to see if it can be verified and scored.
- `site_url` not configured — all duplicate/SERP-gap judgments used competitor-list fallback (Healthline, WebMD, STAT, etc.) rather than confirmed self-check.
- No tool outages this run; Google Trends and Google News Radar both fully available.
- Run archived to `data/run_history.yaml`; dashboard written to `outputs/daily_newsroom_dashboard/2026-10-24.html`.